MetaVia (MTVA) investor relations material

Scientific rationale and program highlights

• DA-1726 is a GLP-1/glucagon dual agonist with a unique 3:1 balance, aiming for superior glucose control and fat reduction in obesity patients compared to competitors with different ratios.

• Phase 1 results for DA-1726 up to 32 mg showed strong glucose control and over 4% weight loss in four weeks, with a favorable safety profile.

• DA-1241 is an oral GPR-119 agonist that increases natural GLP-1 production and has direct hepatic effects, showing compelling Phase 2A data in presumed NASH patients.

• DA-1241 demonstrated an excellent safety profile in a 16-week Phase 2A trial, supporting further development and potential for combination therapies.

Differentiation, safety, and efficacy

• DA-1726’s 3:1 GLP-1/glucagon ratio is designed to optimize both glucose control and fat loss, differentiating it from competitors like pemvidutide and retatrutide.

• Early data indicate lower discontinuation rates due to adverse events compared to other dual agonists, with most GI side effects resolving after initial doses.

• The ongoing 48 mg cohort in Phase 1 is testing higher efficacy and safety without titration, targeting at least 7% weight loss over eight weeks.

• Advanced imaging and biomarker analysis (DEXA, FibroScan, HbA1c) are being used to assess fat loss, lean mass, and liver effects.

Strategic direction and partnerships

• Plans include moving DA-1726 to Phase 2 with a focus on longer studies and broader patient populations, especially those with type 2 diabetes and NASH.

• Active pursuit of partnerships or collaborations, particularly with large pharmaceutical companies seeking differentiated clinical-stage assets.

• DA-1241’s development strategy centers on combination therapies, especially with FGF21 analogues and GLP-1s, to address the complex NASH landscape.

• Ongoing discussions with companies closer to approval for ideal collaboration opportunities.